IR@PKUHSC  > 北京大学第一临床医学院  > 消化科
学科主题临床医学
Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy
Gu, Q.; Xia, H. H. X.; Wang, J. D.; Wong, W. M.; Chan, A. O. O.; Lai, K. C.; Chan, C. K.; Yuen, M. F.; Fung, F. M. Y.; Wong, K. W.; Lam, Sx.; Wong, B. C. Y.
关键词Helicobacter pylori clarithromycin antibiotic resistance H. pylori eradication
刊名DIGESTION
2006
DOI10.1159/000094040
73期:2-3页:101-106
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]ERADICATION RATES ; ANTIMICROBIAL RESISTANCE ; HIGH PREVALENCE ; DUODENAL-ULCER ; UNITED-STATES ; RABEPRAZOLE ; INFECTION ; METRONIDAZOLE ; OMEPRAZOLE ; AMOXICILLIN
英文摘要

Aim: To determine the antibiotic susceptibility of Helicobacter pylori and evaluate the efficacy of a clarithromycin-based triple therapy in relation to antibiotic resistance. Methods: Consecutive patients referred for upper endoscopy due to dyspeptic symptoms were recruited. Gastric biopsies were obtained for the CLO test, histology and culture. Antibiotic susceptibility was assessed by the E-test. Patients with H. pylori infection received rabeprazole 20 mg, clarithromycin 500 mg, and anoxicillin 1,000 mg, all twice daily for 7 days. Results: of 234 patients recruited, 124 were H. pylori-positive and culture was successful in 102 patients. The updated prevalences of resistance to clarithromycin, amoxicillin and metronidazole were 7.8, 0 and 39.2%, respectively. A total of 86 patients received 1-week triple therapy with rabeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg, all twice daily, and 81 patients attended the follow-up test. Eradication rates by per-protocol and intention-to-treat analysis were 92.6 and 87.2%, respectively. The eradication rate by per protocol was significantly higher in patients with clarithromycin-susceptible strains than in those with clarithromycin-resistant strains (98.6 vs. 28.6%, p < 0.001). Conclusion: Clarithromycin resistance reduces the clinical efficacy of clarithromycin-based triple therapy. However, due to the low prevalence of clarithromycin resistance, clarithromycin-based therapy is still the first choice for clinical use. Copyright (c) 2006 S. Karger AG, Basel.

语种英语
WOS记录号WOS:000239427800005
引用统计
被引频次:9[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59035
专题北京大学第一临床医学院_消化科
作者单位1.Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
2.Peking Univ, Hosp 1, Dept Gastroenterol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Gu, Q.,Xia, H. H. X.,Wang, J. D.,et al. Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy[J]. DIGESTION,2006,73(2-3):101-106.
APA Gu, Q..,Xia, H. H. X..,Wang, J. D..,Wong, W. M..,Chan, A. O. O..,...&Wong, B. C. Y..(2006).Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy.DIGESTION,73(2-3),101-106.
MLA Gu, Q.,et al."Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy".DIGESTION 73.2-3(2006):101-106.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Gu, Q.]的文章
[Xia, H. H. X.]的文章
[Wang, J. D.]的文章
百度学术
百度学术中相似的文章
[Gu, Q.]的文章
[Xia, H. H. X.]的文章
[Wang, J. D.]的文章
必应学术
必应学术中相似的文章
[Gu, Q.]的文章
[Xia, H. H. X.]的文章
[Wang, J. D.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。